Answers are grounded in this paper and cite their sources.
Cisplatin resistance remains a major challenge in non-small cell lung cancer (NSCLC) therapy. This study investigated whether wogonin, a natural flavonoid, can reverse cisplatin resistance and explored the underlying mechanisms. The effects of wogonin alone and in combination with cisplatin (DDP) were evaluated in DDP-sensitive (A549) and DDP-resistant (A549/DDP) NSCLC cells using CCK-8, colony formation, wound healing, and Transwell assays. Cell death was characterized by measuring ferroptosis markers (ROS, MDA, GSH, JC-1). Potential targets were identified via RNA sequencing and validated by molecular docking and dynamics simulations. The involvement of the HO-1/PPARγ/PGC-1α axis and mitochondrial quality control was assessed using immunofluorescence, western blotting, qPCR, and electron microscopy, with Zinc Protoporphyrin as an HO-1 inhibitor. In vivo efficacy was confirmed in an NCI-H1975 xenograft model. Wogonin synergized with DDP to inhibit proliferation, migration, and invasion of A549/DDP cells. The combination synergistically induced ferroptosis, characterized by elevated ROS and MDA, depleted GSH, and downregulated SLC7A11. GPX4 was not examined in the current dataset and will be included in follow-up studies. Transcriptomic and in silico analyses identified HO-1, PPARγ, PGC-1α, and SLC7A11 as potential targets. Functionally, the combination suppressed the HO-1/PPARγ/PGC-1α axis and SLC7A11; pharmacological HO-1 inhibition with ZnPP partially reversed these changes. No genetic causality is claimed. Mechanistically, it disrupted mitochondrial quality control by inhibiting biogenesis (reduced mtDNA transcripts, Nrf1/2) and blocking protective mitophagy (altered LC3B localization, reduced Parkin, accumulated p62). In vivo, the combination potently suppressed tumor growth and downregulated the HO-1/PPARγ/PGC-1α axis. These findings suggest that wogonin may reverse cisplatin resistance in NSCLC by inducing ferroptosis and disrupting mitochondrial quality control, potentially through the HO-1/PPARγ/PGC-1α axis. This axis should be considered a working hypothesis pending genetic validation.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: